Gut microbiome data from Korean non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs)
Stool samples for both shotgun and amplicon sequencing were collected at screening (n = 92), after C2D1 (n = 82), and at progression (n = 36) to identify factors associated with ICI response.